CSF1R and glioblastoma: It was further demonstrated that immune responses in GBM patients could be enhanced by co-targeting TAM-associated CSF-1R signalling and PD-1 checkpoints, especially in GBM patients who did not respond to single ICB therapy targeting PD-1 (72).